Three Strikes, Same Deficiency: How Elevar Therapeutics Turned a Solvable Manufacturing Problem Into a Patient Crisis

Pull up the GlobeNewswire press release from July 10, 2026. Elevar Therapeutics announces receipt of a third Complete Response Letter from the FDA for the combination of rivoceranib and camrelizumab as a first-line treatment for unresectable or metastatic hepatocellular carcinoma. The reason, again: manufacturing deficiencies. Now open the Fierce Pharma coverage of the second rejection and the reporting from the first. The language is nearly identical across all three. At some point, “additional manufacturing concerns” stops being a regulatory setback and starts being an indictment of whether this sponsor ever had a credible remediation plan.

The Phase 3 CARES-310 study behind this application produced a median overall survival of 22.1 months for camrelizumab plus rivoceranib versus sorafenib in unresectable HCC patients. That is a clinically meaningful signal. Patients with unresectable liver cancer are running out of time at the rate of months, not quarters. And while the efficacy data sat validated and ready, Elevar and its partner Jiangsu Hengrui Pharmaceuticals spent two years failing to answer the same manufacturing questions to the FDA’s satisfaction. The question this column is going to answer: what does a three-CRL, same-deficiency failure reveal about how this sponsor has managed the most operationally demanding half of drug development?

A Failure With a Timestamp on It

The first CRL arrived in May 2024. That is the established baseline. At that moment, Elevar and Hengrui received a written regulatory document from the FDA telling them, in specific terms, what their manufacturing submission was missing. That document is a gift. It is a roadmap. The entire value proposition of a Complete Response Letter, from the sponsor’s perspective, is that you now know exactly what the deficiency is and can build a remediation against it.

Jiangsu Hengrui’s manufacturing history made this an especially high-stakes gift to receive. The FDA had already issued a Warning Letter to Jiangsu Hengrui Pharmaceuticals Co., Ltd. following an inspection of its Huanghe Road facility that identified significant CGMP violations, with the Warning Letter preceded by an eight-observation Form 483. Eight observations. That inspection record should have told Elevar’s leadership team exactly what category of scrutiny Hengrui’s manufacturing sites would face from CDER reviewers. Instead, the pattern that preceded the first CRL continued through the second and into the third.

By the time the second rejection landed, the operational calculus should have shifted fundamentally. A first CRL can be attributed to a gap in the submission. A second CRL on the same issue means the remediation failed. Either the root cause was misidentified, the corrective actions were inadequate, the facility-level changes were not verified before resubmission, or the pre-submission meeting with the FDA did not surface the residual deficiency. Each of those explanations is a distinct operational failure with a named owner. None of them are accidents.

The third rejection removes the possibility of calling this a miscommunication. Three CRLs citing manufacturing deficiencies across approximately two years means Elevar submitted a response it believed was adequate, FDA reviewers opened it and disagreed, and somehow that cycle repeated. Elevar’s own press release states the companies are now “developing a new resubmission plan.” That phrase, appearing after a third rejection, should alarm every compliance officer reading it. A resubmission plan that is being developed in July 2026 is a plan that apparently did not exist in sufficient rigor before the July 2026 submission was filed.

The Accountability Gap in a Two-Party Program

Multi-party development programs between U.S. commercial sponsors and Chinese manufacturing partners carry a known and specific regulatory risk profile. Elevar’s role in this partnership is to translate FDA expectations into actionable requirements for Hengrui’s manufacturing sites and then verify, before submission, that those requirements have been met. That function has a name in 21 CFR Part 211 terms: it is quality oversight of contract manufacturers. The regulation does not create an exemption for international partnerships or for situations where the manufacturing partner is also a co-developer with its own regulatory affairs team.

The FDA’s Warning Letter to Hengrui’s Huanghe Road facility identified CGMP violations that were serious enough to generate eight 483 observations before escalating to Warning Letter status. Elevar’s technical and regulatory teams had access to that inspection record. The reasonable professional response to an eight-observation 483 at your manufacturing partner’s facility, while your NDA is under active review, is to conduct an independent quality audit, map every observation to your CMC submission, and verify remediation before the next submission cycle touches that facility’s data. The public record does not show evidence that this happened effectively, because if it had, the third CRL would not have cited manufacturing deficiencies.

There is a structural problem here that goes beyond Elevar specifically. When a commercial sponsor depends on an overseas manufacturing partner for CMC compliance, the sponsor’s quality agreement with that partner must carry the same enforcement weight as an internal quality system. Every CMC submission checkpoint, every pre-inspection audit, every FDA Type B meeting preparation session must involve both parties at the technical level. If the sponsor’s regulatory team is writing submission language while the partner’s manufacturing team is operating under unresolved 483 observations, the NDA is built on a foundation that FDA inspectors will find structurally unsound. The rivoceranib-camrelizumab program appears to have operated under exactly that disconnect, three separate times.

What Sponsors and FDA-Watchers Must Do Differently Now

Sponsors running multi-party programs with offshore manufacturing partners need a hard policy: no resubmission after a manufacturing CRL without an independently verified pre-approval inspection readiness audit of every facility named in the NDA. Not an internal audit conducted by the partner. An independent audit, with findings reviewed by the sponsor’s head of quality before the resubmission cover letter is signed. That standard is operationally achievable. Elevar had two CRL cycles to implement it. The third CRL suggests it was not implemented.

For sites and clinical operations teams watching this case, the lesson runs upstream. CARES-310 generated a 22.1-month median overall survival that outperformed sorafenib in unresectable HCC patients. That efficacy signal is sitting on a shelf while patients who might have benefited from this combination are being enrolled in other trials or progressing on older regimens. Clinical trial teams invest years in patient recruitment, data collection, and endpoint adjudication. When the CMC function fails to match that rigor, the clinical work becomes irrelevant to the patients it was designed to help. That is the cost that never appears in a press release.

FDA-watchers should be tracking whether CDER issues any public-facing commentary on the three-CRL pattern in this program, and whether the agency’s pre-NDA meeting process for resubmissions is being used at all before Elevar files a fourth time. The agency has the authority to require a Type A meeting before accepting a resubmission when there is documented, repeated non-compliance in a specific CMC area. If that mechanism is not being used here, it should be.

The next signal to watch is whether Elevar’s “new resubmission plan” includes a publicly disclosed timeline and a confirmed pre-submission meeting with the FDA, because a fourth submission without either of those in place would tell you everything you need to know about whether anything has actually changed in this program’s quality infrastructure.

References

1. Endpoints News — “FDA rejects Hengrui-Elevar liver cancer drug combo for third time”
2. GlobeNewswire / Elevar Therapeutics — “Elevar Therapeutics Receives FDA Complete Response Letter for Combination of Rivoceranib and Camrelizumab” (July 10, 2026)
3. Fierce Pharma — “FDA rejects Hengrui-Elevar PD-1 liver cancer combo for 3rd time”
4. FDA Warning Letter — Jiangsu Hengrui Pharmaceuticals Co., Ltd. (July 11, 2024)
5. Elevar Therapeutics — “CARES-310 Phase 3 Results: Camrelizumab Plus Rivoceranib OS Data” (September 2022)
6. Oncology News Central — “FDA Rejects Liver Cancer Combo for Third Time”
7. OncLive — “FDA Issues Third CRL for Rivoceranib Plus Camrelizumab in First-Line HCC Over Additional Manufacturing Concerns”